N
Nicola Vianelli
Researcher at University of Bologna
Publications - 243
Citations - 7780
Nicola Vianelli is an academic researcher from University of Bologna. The author has contributed to research in topics: Ruxolitinib & Essential thrombocythemia. The author has an hindex of 45, co-authored 223 publications receiving 6504 citations.
Papers
More filters
Journal ArticleDOI
Liposomal Amphotericin B as Initial Therapy for Invasive Mold Infection: A Randomized Trial Comparing a High–Loading Dose Regimen with Standard Dosing (AmBiLoad Trial)
Oliver A. Cornely,Johan Maertens,Mark Bresnik,Ramin Ebrahimi,Andrew J. Ullmann,Emilio Bouza,Claus Peter Heussel,Olivier Lortholary,Christina Rieger,Angelika Boehme,Mickael Aoun,Heinz-August Horst,Anne Thiebaut,Markus Ruhnke,Dietmar Reichert,Nicola Vianelli,Stefan W. Krause,Eduardo Olavarria,Raoul Herbrecht +18 more
TL;DR: In highly immunocompromised patients, the effectiveness of 3 mg/kg of liposomal amphotericin B per day as first-line therapy for invasive aspergillosis is demonstrated, with a response rate of 50% and a 12-week survival rate of 72%.
Journal ArticleDOI
Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments
Valerio De Stefano,Tommaso Za,Elena Rossi,Alessandro M. Vannucchi,Marco Ruggeri,Elena Maria Elli,Caterina Micò,Alessia Tieghi,Rossella R. Cacciola,Cristina Santoro,Giancarla Gerli,Nicola Vianelli,Paola Guglielmelli,Lisa Pieri,Francesca Scognamiglio,Francesco Rodeghiero,Enrico Pogliani,Guido Finazzi,Luigi Gugliotta,Roberto Marchioli,Giuseppe Leone,Tiziano Barbui +21 more
TL;DR: In patients with polycythemia vera and essential thrombocythemia, cytoreduction protects against recurrentThrombosis, particularly after acute coronary syndrome, and the contemporary use of oral anticoagulants or antiplatelet agents further improves the protective effect.
Journal ArticleDOI
Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience.
Maria Gabriella Mazzucconi,Paola Fazi,Sayla Bernasconi,Giulio Rossi,Giuseppe Leone,Luigi Gugliotta,Nicola Vianelli,Giuseppe Avvisati,Francesco Rodeghiero,Angela Amendola,Carlo Baronci,Cecilia Carbone,Stefano Quattrin,Giuseppe Fioritoni,Giulio D'Alfonso,Franco Mandelli +15 more
TL;DR: A schedule of 3 cycles of HD-DXM pulses will be compared with standard prednisone therapy in the next randomized Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA) trial.
Journal ArticleDOI
Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia
Francesco Zaja,Michele Baccarani,Patrizio Mazza,Monica Bocchia,Luigi Gugliotta,Alfonso Zaccaria,Nicola Vianelli,Marzia Defina,Alessia Tieghi,Sergio Amadori,Selenia Campagna,Felicetto Ferrara,Emanuele Angelucci,Emilio Usala,Silvia Cantoni,Giuseppe Visani,Antonella Fornaro,Rita Rizzi,Valerio De Stefano,Francesco Casulli,Marta Lisa Battista,Miriam Isola,Franca Soldano,Enrica Gamba,Renato Fanin +24 more
TL;DR: In this article, a randomized trial investigated rituximab efficacy in previously untreated adult ITP patients with a platelet count of 20 x 10(9)/L or less.
Journal ArticleDOI
Efficacy and safety of splenectomy in immune thrombocytopenic purpura: long-term results of 402 cases.
Nicola Vianelli,Galli M,de Vivo A,Intermesoli T,B Giannini,Maria Gabriella Mazzucconi,T Barbui,Tura S,Baccaranion M +8 more
TL;DR: This study shows that splenectomy is a safe procedure and effective in approximately two thirds of patients with chronic ITP, and further studies are required to establish whether surgery-sparing treatments of Chronic ITP have similar or even superior efficacy, risk and cost ratios compared to splenection.